New drug duo tested in fight against tough leukemia
NCT ID NCT04666649
Summary
This early-stage study tested the safety and best dose of a two-drug combination (venetoclax pills plus pegcrisantaspase infusions) for adults with acute myeloid leukemia (AML) that has returned or didn't respond to previous treatments. The goal was to see if this new combination could help control the disease, potentially leading to remission or allowing patients to proceed to a stem cell transplant. The study involved 27 participants and focused on finding a dose that was both effective and tolerable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.